Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.45 |
| ▸ | MTOR | P42345 | 14/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711360 | 0.85 | MTOR (0.62) | SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6178078 | 0.80 | HTT (0.61) | SMN1; SMN2MAPK1HTTPIK3CDPIK3CA | |
| SCHEMBL3790546 | 0.80 | TP53 (0.37) | SMN1; SMN2MAPK1HTTPIK3CDPIK3CA | |
| SCHEMBL3787311 | 0.80 | NPM1 (0.39) | SMN1; SMN2MAPK1HTTTSHRGALR3 | |
| SCHEMBL6488650 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPK1HTTPIK3CDPIK3CA | |
| SCHEMBL3785846 | 0.76 | PIK3CD (0.45) | SMN1; SMN2MAPK1HTTPIK3CDPIK3CA | |
| Hydrochloric Acid SCHEMBL3786325 | 0.76 | PIK3CD (0.49) | SMN1; SMN2MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3789188 | 0.75 | PIK3CD (0.46) | SMN1; SMN2MAPK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL4083024 | 0.72 | L3MBTL1 (0.56) | SMN1; SMN2MAPK1HTTTSHRRAB9A | |
| SCHEMBL19474497 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPK1HTTPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | SMN1; SMN2 3660/4885MAPK1 291/4885HTT 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.